For people with chronic obstructive pulmonary disease (COPD), characterized by cough and shortness of breath, Anoro Elipta (umeclidinium-vilanterol) may work better than other approved COPD medications at reducing the risk of disease flares. That’s according to a new federally funded study that used U.S. insurance data to compare…
News
A novel test based on the levels and composition of certain proteins in mucus, called mucins, may help assess lung health in people with chronic obstructive pulmonary disease (COPD), according to a new study. Findings show that higher Mucin Quantitative Score (MUCQ) values were significantly associated with worse lung…
The first person with chronic obstructive pulmonary disease (COPD) has now been dosed with BBT002, an experimental medication being developed by Bambusa Therapeutics, in an ongoing Phase 1b clinical trial. The trial (NCT06944925) is evaluating BBT002’s safety and pharmacological properties against a placebo in up to 98…
Mabwell’s experimental therapy 9MW1911 may reduce the frequency of moderate to severe exacerbations in people with chronic obstructive pulmonary disease (COPD), according to data from a completed Phase 2a clinical trial. The results were announced in a press release from Mabwell. The company is now conducting a…
The American Lung Association Research Institute is investing $22 million to advance research and support care for lung disease, including chronic obstructive pulmonary disease (COPD). “Research is the foundation for every breakthrough that improves lung health and saves lives,” said Harold Wimmer, president and CEO of the…
November marks COPD Awareness Month in the U.S. — a time, advocates say, to educate communities, inspire action, and support those with chronic obstructive pulmonary disease (COPD). World COPD Day will be observed Nov. 19. Each November, the COPD Foundation and the lung health community lead a monthlong…
A Phase 3 clinical trial testing AstraZeneca’s injection therapy benralizumab as a potential treatment for chronic obstructive pulmonary disease (COPD) has failed to meet its main goal of showing the therapy’s superiority over a placebo in terms of the ability to reduce the rate of moderate or…
A new survey from the COPD Action Alliance shows that people living with chronic obstructive pulmonary disease (COPD) in the U.S. often have difficulty getting proper care because of barriers to health insurance, high costs, and limited access to treatment. According to the alliance, a nationwide advocacy network,…
Genentech has announced mixed top-line results from two global clinical trials testing its treatment candidate astegolimab in people with moderate to very severe chronic obstructive pulmonary disease (COPD). Both one-year trials aimed to demonstrate that the therapy was superior to a placebo at reducing the annual rate of…
Digital inhalers that measure and record inhalation data and that can remotely monitor patients may help predict impending chronic obstructive pulmonary disease (COPD) exacerbations, that is, episodes when lung symptoms suddenly worsen. That’s according to data from a Phase 4 observational pilot study (NCT05241288) that followed 40 COPD…
Recent Posts
- A diagnosis is a map that shows our way through an unknown land
- US study names COPD therapy Anoro Elipta top choice for new patients
- Applying wise old sayings to a different body with COPD
- I maintain my morning rituals to keep COPD from shrinking my world
- Living with COPD isn’t a test that I have to pass